Get the Stockscreener App
5.02
2.87%
0.14
After Hours:
5.16
0.14
+2.79%
Perspective Therapeutics Inc stock is traded at $5.02, with a volume of 2.06M.
It is up +2.87% in the last 24 hours and up +108.30% over the past month.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
See More
Previous Close:
$4.88
Open:
$4.86
24h Volume:
2.06M
Relative Volume:
0.63
Market Cap:
$571.85M
Revenue:
$6.96M
Net Income/Loss:
$-46.51M
P/E Ratio:
-29.25
EPS:
-0.1716
Net Cash Flow:
$-37.99M
1W Performance:
+8.42%
1M Performance:
+108.30%
6M Performance:
+26.13%
1Y Performance:
+65.68%
1-Day Range:
$4.67
$5.08
1-Week Range:
$4.37
$5.08
52-Week Range:
$1.60
$6.16
Perspective Therapeutics Inc Stock (CATX) Company Profile
Name
Perspective Therapeutics Inc
Sector
Industry
Phone
509-375-1202
Address
350 Hills Street, Suite 106, Richland
Compare CATX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
5.02 | 555.90M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
111.47 | 197.52B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
365.85 | 139.09B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
100.88 | 129.59B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.12 | 108.96B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
76.44 | 46.04B | 6.07B | 1.06B | 799.60M | 1.8527 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Resumed | Truist | Buy |
| Oct-10-25 | Initiated | BTIG Research | Buy |
| Mar-13-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-01-24 | Initiated | Wedbush | Outperform |
| Sep-25-24 | Initiated | Truist | Buy |
| Jul-25-24 | Initiated | BofA Securities | Buy |
| May-09-24 | Initiated | Cantor Fitzgerald | Overweight |
View All
Perspective Therapeutics Inc Stock (CATX) Latest News
Activity Recap: Does Perspective Therapeutics Inc stock have upside surprise potentialExit Point & Technical Buy Zone Confirmations - baoquankhu1.vn
Perspective Therapeutics (CATX) Is Up 92.6% After $175M Equity Raise To Fund Targeted Alpha Therapies – Has The Bull Case Changed? - Yahoo Finance
Perspective Therapeutics Raises Capital to Advance Radiopharmaceutical Pipeline - TipRanks
Perspective Therapeutics Prices Approx. $175 Mln Offering Of Shares And Pre-Funded Warrants - Nasdaq
Perspective Therapeutics (CATX) Raises $175 Million Through Stoc - GuruFocus
Perspective Therapeutics shares rise after $175 million offering By Investing.com - Investing.com South Africa
Perspective Therapeutics shares rise after $175 million offering - Investing.com
Perspective Therapeutics jumps after $175 mln equity offering - TradingView
Perspective Therapeutics (CATX) Announces $175M Public Offering - GuruFocus
Perspective Therapeutics prices 39.58M shares at $3.79 in underwritten offering - TipRanks
Perspective Therapeutics prices $175M equity offering; shares up - MSN
Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - marketscreener.com
Perspective Therapeutics taps $175M stock sale to fund cancer radiopharma work - Stock Titan
Comparing Perspective Therapeutics (NASDAQ:CATX) & Biosig Technologies (NASDAQ:STEX) - Defense World
Brokerages Set Perspective Therapeutics (NASDAQ:CATX) Target Price at $11.17 - Defense World
A Look At Perspective Therapeutics (CATX) Valuation After New VMT-α-NET Trial And Pipeline Updates - Yahoo Finance
Perspective Therapeutics: VMT-A-NET Presses On In SSTR2-Solid Tumor Targeting Space (CATX) - Seeking Alpha
Perspective Therapeutics (CATX) Rating Maintained, Price Target Raised by HC Wainwright & Co. | CATX Stock News - GuruFocus
Why Perspective Therapeutics (CATX) Is Up 59.6% After New VMT-α-NET Trial Data And Expansion Plans - Sahm
Perspective Therapeutics (NASDAQ:CATX) Given Average Rating of "Buy" by Analysts - MarketBeat
Perspective Therapeutics stock price target raised to $12 from $10 at H.C. Wainwright By Investing.com - Investing.com Canada
Perspective Therapeutics (NASDAQ:CATX) Given Outperform Rating at Wedbush - MarketBeat
CATX: Wedbush Reiterates Outperform Rating with Maintained Price Target | CATX Stock News - GuruFocus
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors - Sahm
What is the next catalyst for Perspective Therapeutics Inc.2025 Fundamental Recap & AI Powered Buy and Sell Recommendations - mfd.ru
Perspective Therapeutics stock price target raised to $12 from $10 at H.C. Wainwright - Investing.com Canada
Perspective Therapeutics stock (CATX) steadies before the open after 66% jump — what investors watch next - TechStock²
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Growth Report: Does Perspective Therapeutics Inc stock have upside surprise potential2025 Investor Takeaways & Short-Term Swing Trade Alerts - baoquankhu1.vn
Perspective Therapeutics (NYSEAMERICAN:CATX) Shares Down 4.4%Time to Sell? - MarketBeat
Can Perspective Therapeutics Inc expand into new marketsQuarterly Trade Review & Precise Buy Zone Identification - baoquankhu1.vn
Signal Recap: Whats the MACD signal for APLSPortfolio Performance Summary & Accurate Intraday Trading Signals - baoquankhu1.vn
Reviewing Perspective Therapeutics (NASDAQ:CATX) & CapsoVision (NASDAQ:CV) - Defense World
Analyzing Carlsmed (NASDAQ:CARL) and Perspective Therapeutics (NASDAQ:CATX) - Defense World
Aug Momentum: Is Perspective Therapeutics Inc part of any major indexRate Hike & Community Supported Trade Ideas - baoquankhu1.vn
CEO Moves: Is Perspective Therapeutics Inc part of any major indexMarket Performance Recap & Weekly Return Optimization Plans - baoquankhu1.vn
Critical Contrast: Perspective Therapeutics (NASDAQ:CATX) and Shoulder Innovations (NYSE:SI) - Defense World
Perspective Therapeutics, Inc Updates Corporate Presentation on Radiopharmaceuticals - TradingView — Track All Markets
Perspective Therapeutics (NASDAQ:CATX) Receives “Buy” Rating from BTIG Research - Defense World
BTIG Reiterates 'Buy' Rating for Perspective Therapeutics (CATX) with $14 PT | CATX Stock News - GuruFocus
Perspective Therapeutics' (CATX) Buy Rating Reiterated at BTIG Research - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Short Covering: Can Perspective Therapeutics Inc generate free cash flowEarnings Overview Summary & Consistent Growth Equity Picks - baoquankhu1.vn
Perspective Therapeutics outlines 2026 clinical and manufacturing priorities - TipRanks
Perspective Therapeutics Provides Business Updates and Strategic Priorities - TradingView
Perspective Therapeutics Provides Business Updates and - GlobeNewswire
How Perspective Therapeutics Inc. stock benefits from global expansionPerformance Line Overview & walk-ready comfort choices - Улправда
Perspective Therapeutics Reports Positive Interim Neuroendocrine Tumor Data - TipRanks
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium - The Manila Times
Experimental targeted radiation shows tumor shrinkage in early trial - Stock Titan
Will Perspective Therapeutics Inc. stock attract ESG investorsEarnings Recap Summary & Weekly High Potential Stock Alerts - Улправда
Perspective Therapeutics Inc Stock (CATX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
0.31%
Cap:
|
Volume (24h):